Table 3. Statin use and colorectal cancer-specific / overall survival stratified by biomarker subgroups.

	Colorectal cancer-specific survival					Overall survival
	Statin non-user	Statin user	HR (95%CI)a user vs non-user	P-value	P for interaction	Statin non-user	Statin user	HR (95%CI)b user vs non-user	P-value	P for interaction
	No. of deaths/patients					No. of deaths/patients
Stratified by patterns of p53 immunostaining
Normal	43/182	16/60	1.31 (0.67–2.56)	0.43	0.51	75/182	22/60	0.67 (0.34–1.30)	0.24	0.60
Aberrant	98/263	30/98	0.80 (0.52–1.24)	0.33		127/263	46/98	0.91 (0.63–1.32)	0.61
Stratified by HMGCR expression
H-score <median	79/231	26/69	1.10 (0.66–1.84)	0.71	0.08	118/231	34/69	0.78 (0.49–1.25)	0.30	0.28
H-score ⩾median	63/214	20/89	0.69 (0.40–1.18)	0.17		85/214	34/89	0.77 (0.49–1.22)	0.26
Stratified by KRAS mutation status
Wild-type	83/262	26/103	0.73 (0.44–1.19)	0.20	0.05	116/262	40/103	0.68 (0.44–1.04)	0.08	0.07
Mutated	57/176	19/53	1.21 (0.70–2.21)	0.50		84/176	27/53	1.00 (0.61–1.66)	0.98

Abbreviations: CI=confidence intervals; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; MSI=microsatellite instability.

^aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, ECOG performance status, family history of colorectal cancer, adjuvant chemotherapy use, stage, and aspirin use.

^bMultivariable model adjusted for all variables in footnote a and also adjusted for Charlson Comorbidity Index score.